Cellusion Inc.

Cellusion have developed three main technologies for solving global cornea shortage issue, which are novel cell transplantation method for Bullous Keratopathy treatment, mass production technology to produce corneal endothelial cell from iPS cells, spheroid transplantation method to enhance the treatment efficacy. With these cellular technology breakthroughs, we will contribute to provide the clear vision of the future for worldwide patients.


Business information

Company name

Cellusion Inc.




Tokyo, JP

Spinout from

Other location(s)

Technology validation



Value of patent(s)

Business stage

Series A stage
Series B stage

Target exit

IPO in Japan
Trade sales

Next investment requirement

$2m to $3m

Message to the business partners

Cellusion always welcomes to join our team as whoever solving global blindness issue together. Regardless of collaboration or investment etc., please feel free to contact us. Why don’t we discuss what we can do together?

Key literatures

To be updated